This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shaarawy, M. Articles by Abdel-Aziz, O. Search for Related Content PubMed PubMed Citation Articles by Shaarawy, M. Articles by Darwish, N. A. Articles by Abdel-Aziz, O. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information High Risk Pregnancy Pregnancy Uterine Cancer Social Bookmarking                         What's this?

Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Gestrational Trophoblastic Diseases

Nabil A. Darwish, MD

Omar Abdel-Aziz, MD

Department of Obsterics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt

Objective: To investigate serum interleukin-2 (IL-2) and soluble interleukin-2 receptor (SIL-2) levels in gestational trophoblastic diseases (GTD).

Methods: Sixty-six patients with GTDs and 23 first-trimester healthy pregnant women (controls) participated in this study. According to the World Health Organization scoring system, GTDs were subgrouped into the following groups: 30 hydatidiform mole spontaneous regression (HMRS), 12 postmolar gestational trophoblastic tumors of high risk (PMHR), 14 low-risk choriocarcinomas, and ten high-risk choriocarcinomas. Before treatment, a blood sample from each case was assayed for ß-hCG by radioimmunoassay, IL-2 by IRMA, and SIL-2R by enzyme-linked immunosorbent assay. Follow-up ß-hCG assays were carried out at weekly intervals after treatment for 3 months, then monthly for 1 year.

Results: Serum IL-2 levels in all subgroups of GTD were significantly lower than that of controls. Meanwhile, there were concomitant significant elevations of serum SIL-2R, showing mean rises of 3.86-fold, 3.9-fold, twofold, and 6.1-fold for cases of HMSR, PMHR, low-risk choriocarcinoma, and high-risk carcinoma, respectively. All cases of high-risk choriocarcinoma revealed abnormally high SIL-2R values. There was a significant positive correlation between serum ß-hCG and SIL-2R concentrations.

Conclusion: The possible causes of IL-2 decreases and SIL-2R increase may indicate a defective immune response in GTDs. The high correlation between SIL-2R level and tumor burden suggests the use of serum SIL-2R assay for disease monitoring: SIL-2R is indirect maker of tumor activity, and its is useful in the differential diagnosis of GTD because a normal value of serum SIL-2R excludes high-risk cases of choriocarcinoma.

Key Words: Interleukin-2 • soluble interleukin-2 receptor • gestational trophoblastic disease

Journal of the Society for Gynecologic Investigation, Vol. 3, No. 1, 39-46 (1996)
DOI: 10.1177/107155769600300109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?